Philadelphia’s startup ecosystem climbs 15 spots into the top 30 worldwide, report says

Philadelphia’s startup scene is ranked amongst the best-performing in the world according to Startup Genome.

Article from Philadelphia Business Journal 

Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream, a Topical JAK Inhibitor, for the Treatment of Atopic Dermatitis (AD)

The U.S. Food and Drug Administration has approved Opzelura™ cream for short-term and non-continuous chronic treatment of atopic dermatitis.

Article from Business Wire

Penn Medicine Awarded $6 Million to Advance Understanding of Human Genome Function in Health and Disease

Penn Medicine is one of 30 sites chosen by the National Institute of Health to serve as an Impact of Genomic Variation on Function investigator.

Article from Penn Medicine

September 16th, 2021|Cell and Gene Therapy, Investments, Largest Employers, Life Sciences, Regional News Roundup|Comments Off on Penn Medicine Awarded $6 Million to Advance Understanding of Human Genome Function in Health and Disease

Rite Aid Corp. to move HQ to Philadelphia Navy Yard

Rite Aid Corp. signed a lease for a 23,500 square foot space at 1200 Intrepid Ave for their “enterprise headquarters” as part of an effort to redefine how they envision their employees working as a result of the pandemic.

Article from Philadelphia Business Journal

September 14th, 2021|Company Locates/Expansion Announcements, Innovation, Real Estate, Regional News Roundup|Comments Off on Rite Aid Corp. to move HQ to Philadelphia Navy Yard

Can­cer gi­ant Roche splash­es in­to cell ther­a­py with $3B+ Adap­ti­m­mune deal for off-the-shelf drugs

Roche’s Genetech has signed a deal to partner with Adaptimmune on off-the-shelf T cell therapies.

Article from Endpoints News

September 10th, 2021|Cell and Gene Therapy, Investments, Regional News Roundup|Comments Off on Can­cer gi­ant Roche splash­es in­to cell ther­a­py with $3B+ Adap­ti­m­mune deal for off-the-shelf drugs

Penn spinout led by veteran pharma execs emerges from stealth mode, raises $50M to advance gene-editing technology

Director of the University of Pennsylvania’s gene therapy program, Dr. James Wilson, has formed a company specializing in gene editing.

Article from Philadelphia Business Journal

September 9th, 2021|Cell and Gene Therapy, Innovation, Investments, Regional News Roundup|Comments Off on Penn spinout led by veteran pharma execs emerges from stealth mode, raises $50M to advance gene-editing technology
Go to Top